Ipca Laboratories, with a view to enter the largest South-East Asian market is planning to acquire a pharmaceutical company in Indonesia. The company is scouting for an Indonesian company especially with a generic product marketing license. It needs good access to the Indonesian market and an established pharmaceutical company would be good vehicle to market Indian pharma products in Indonesia.
For this acquisition which is to be made within the next few months, Ipca Laboratories has set aside $20 million. It has also shortlisted the number of companies to be acquired but the names have been kept confidential.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.50 |
Dr. Reddys Lab | 1340.80 |
Cipla | 1476.45 |
Lupin | 2160.20 |
Zydus Lifesciences | 972.95 |
View more.. |